Tirzepatide 10mg

Description

Tirzepatide 10mg — dual GIP and GLP-1 receptor agonist, research catalogue listing

Tirzepatide is a dual GIP and GLP-1 receptor agonist studied as a reference compound in incretin co-agonist research. Work in this area generally compares single-receptor and dual-receptor activation, since the two pathways do not behave identically across models. This listing covers the Tirzepatide 10mg presentation supplied by Polaris Peptides for laboratory and investigative work only.

What the Tirzepatide 10mg listing states

Each vial contains lyophilised material with a stated purity of greater than 99% by HPLC-MS, vacuum-sealed and shipped with desiccant. The peptide is supplied as a single strength per vial, not split across multiple containers. Strength is stated in milligrams on the listing itself rather than inferred from the container, and each strength in the catalogue is priced as a separate item so a protocol can be costed without unit conversion by hand.

Before ordering, check the strength against your study protocol. If you need a different strength, review its separate product page.

Choosing the Tirzepatide 10mg presentation

Compare this strength with the quantity required by your protocol. Other available strengths have separate listings and prices.

Handling and storage for Tirzepatide 10mg

Hold the sealed vial dry at −20 °C before use. Once reconstituted, keep the material at 2–8 °C and complete planned work within a defined window rather than holding solutions indefinitely. Protect from light, and avoid repeated freeze–thaw cycles, which degrade peptide material faster than steady cold storage.

On arrival, inspect the vial before storage. Record the batch reference. You may need it when requesting documentation.

Documentation and batch reference

You can ask whether a certificate of analysis is available before ordering. Check that any certificate matches the batch you receive. A certificate for an earlier batch does not cover a later one.

Research context for Tirzepatide

Dual-agonist literature has expanded quickly, and it is worth reading primary studies rather than reviews of reviews. Comparative work on receptor selectivity, signalling bias and downstream metabolic effects is where the detail actually sits. Independent literature is searchable through published studies on PubMed. Regulators have also published statements on unapproved GLP-1 products, which are relevant background for anyone working with this class of compound.

Research-only scope

Tirzepatide 10mg is supplied strictly for research and investigative purposes. It is not for human or veterinary use and is not intended for clinical, therapeutic or diagnostic application. Buyers are responsible for holding the appropriate facilities, training and safety procedures for the work they intend to carry out.